HealthRx.com

Andrew Huberman, Maintenance, and What Happens If You Stop

By
Published Updated Last reviewed
Hormone therapy clinical care image for Andrew Huberman, Maintenance, and What Happens If You Stop
Clinical image for Andrew Huberman, Maintenance, and What Happens If You Stop Image: HealthRX.com clinical image

What Andrew Huberman Has Said Publicly About Testosterone

Andrew Huberman, a tenured neuroscience professor at Stanford School of Medicine, has addressed testosterone protocols across dozens of Huberman Lab podcast episodes. He has discussed the behavioral and physiological effects of testosterone, reviewed peer-reviewed literature on supplementation and hormone optimization, and spoken openly about his own use of various health-optimization protocols.

Huberman has confirmed using supplements and peptides that influence hormonal axes. In multiple episodes and public appearances, he has described protocols involving compounds like tongkat ali, fadogia agrestis, and other over-the-counter agents aimed at supporting endogenous testosterone production. Whether Huberman has used exogenous testosterone (pharmaceutical TRT) is not publicly confirmed as of this writing. His public statements focus on behavioral interventions (sleep, resistance training, cold exposure) and supplement-based optimization rather than prescribed testosterone injections or gels.

This distinction matters. The clinical considerations for someone using OTC testosterone-support supplements differ from those for someone on prescribed exogenous testosterone cypionate or enanthate. The sections below cover both scenarios, because Huberman's audience regularly asks about each.

The Clinical Reality of TRT Discontinuation

For individuals on exogenous testosterone, stopping therapy triggers a recovery period for the hypothalamic-pituitary-testicular axis. During active TRT, exogenous testosterone suppresses gonadotropin-releasing hormone (GnRH), which in turn suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The testes reduce or cease endogenous production in response.

A 2021 review in the Journal of Clinical Endocrinology & Metabolism found that HPTA recovery after TRT discontinuation varies widely. Some men recover baseline testosterone levels within 3 to 6 months. Others, particularly those on therapy for years, may take 12 months or longer. A subset never fully recovers pre-treatment levels, especially men over 45 or those with pre-existing primary hypogonadism.

The symptoms during this recovery window can be significant: fatigue, depressed mood, reduced libido, loss of lean mass, and increased body fat. These are not hypothetical side effects. They are the predictable consequence of low circulating testosterone while the HPTA reboots.

At a glance

  • Public record: Huberman has publicly discussed testosterone-support supplements and behavioral protocols; exogenous TRT use is not publicly confirmed
  • HPTA recovery: After stopping exogenous testosterone, endogenous production may take 3 to 12+ months to return to baseline
  • Fertility impact: TRT suppresses spermatogenesis; recovery of sperm production can lag behind testosterone recovery by months
  • Long-term TRT monitoring: Men on continuous therapy require periodic bloodwork for hematocrit, PSA, lipids, and liver enzymes
  • Supplement-based protocols: OTC testosterone boosters do not suppress the HPTA the way exogenous testosterone does, so "discontinuation" carries different (and generally milder) clinical implications

Fertility: The Overlooked Discontinuation Variable

One of the most clinically important reasons men stop TRT is fertility. Exogenous testosterone acts as a male contraceptive in many users. A landmark study published in The Lancet demonstrated that testosterone-induced azoospermia (zero sperm count) is achievable in a high percentage of men, and the WHO studied testosterone as a potential male contraceptive on this basis.

Recovery of spermatogenesis after TRT cessation follows a separate timeline from testosterone recovery. Data from a 2017 Fertility and Sterility analysis showed median time to recovery of spermatogenesis was approximately 6 months, but some men required over 24 months. Men who used TRT for longer durations before discontinuation faced longer recovery periods.

Huberman has discussed male fertility optimization on his podcast, including the suppressive effects of exogenous testosterone on sperm count. His public guidance has generally steered younger men toward non-suppressive alternatives, which aligns with Endocrine Society guidelines recommending against TRT in men actively seeking fertility.

What "Maintenance" Looks Like on Long-Term TRT

For men who continue TRT indefinitely (which is common, given that hypogonadism is often a chronic condition), the clinical literature outlines clear monitoring requirements.

The 2018 Endocrine Society Clinical Practice Guideline recommends:

  • Hematocrit checks every 6 to 12 months. TRT stimulates erythropoiesis. Hematocrit above 54% increases thrombotic risk and typically requires dose reduction, therapeutic phlebotomy, or both.
  • PSA screening at baseline, 3 to 6 months, then annually. TRT does not cause prostate cancer based on current evidence, but it can accelerate growth of undetected existing tumors.
  • Lipid panels annually. Supraphysiologic testosterone doses can suppress HDL cholesterol. Even therapeutic-range TRT modestly affects lipid profiles in some men.
  • Liver function tests periodically, particularly for oral testosterone formulations (though injectable and transdermal routes carry minimal hepatic risk).
  • Bone density assessment in men who had osteoporosis or low bone density at baseline, as testosterone is protective and discontinuation could reverse gains.

The TRAVERSE trial (2023, published in NEJM) provided the largest randomized safety dataset for TRT to date. It found no significant increase in major adverse cardiovascular events (MACE) in men on testosterone gel vs. placebo over a median follow-up of 33 months. This was a meaningful result: for years, cardiovascular safety had been the primary concern limiting long-term TRT prescribing.

Supplement-Based Protocols: A Different Risk Calculus

Huberman's publicly discussed stack, which has included tongkat ali (Eurycoma longifolia) and fadogia agrestis, operates through a different mechanism than exogenous testosterone. These compounds are theorized to support endogenous production rather than replace it.

A 2022 systematic review in Complementary Therapies in Medicine found that tongkat ali may modestly increase total testosterone in men with initially low levels, with effect sizes generally in the range of 30 to 60 ng/dL. This is a fraction of what TRT achieves (which typically raises levels by 300 to 600 ng/dL from hypogonadal baselines).

The key difference for discontinuation: because these supplements do not suppress the HPTA, stopping them does not trigger the same hormonal crash. The body's endogenous production machinery was never shut down. A man who stops tongkat ali may lose whatever modest boost it provided, but he will not face the weeks-to-months recovery window that follows exogenous testosterone cessation.

Fadogia agrestis has far less clinical data. Animal studies have raised questions about testicular toxicity at high doses. No well-powered human safety trial has been published as of mid-2026. Huberman himself has noted on his podcast that the evidence base for fadogia is thinner than for tongkat ali.

The HealthRX.com Medical Team Take

Huberman's public emphasis on evidence-based optimization is, in our clinical assessment, a net positive for patient education. His audience skews toward health-literate men in their 30s and 40s who are interested in optimization rather than treatment of diagnosed disease. That population needs to hear the message Huberman delivers: behavioral interventions (sleep, resistance training, stress management, body composition) are the foundation, and pharmaceutical intervention carries real trade-offs.

Where we would add nuance: the line between "optimization" and "treatment" blurs when a man's testosterone is in the low-normal range. A total testosterone of 350 ng/dL is technically within reference range at most labs, but symptomatic men at that level may benefit from TRT. The decision to start, and the difficulty of stopping, should be discussed before the first injection, not after.

For any man considering TRT discontinuation, the HealthRX.com Medical Team recommends:

  1. Work with an endocrinologist or urologist, not a wellness clinic operating without proper monitoring protocols.
  2. Get baseline bloodwork before starting so there is a reference point for recovery.
  3. Consider HCG co-therapy during TRT if fertility preservation matters. HCG maintains intratesticular testosterone and supports spermatogenesis even during exogenous testosterone use.
  4. Taper under supervision. Abrupt cessation is the most common approach in clinical practice, but some clinicians use SERMs (clomiphene, enclomiphene) to accelerate HPTA restart. The evidence for this is largely observational, but the rationale is sound.
  5. Monitor mood closely during the recovery window. The 4 to 12 week period after stopping TRT is when depressive symptoms peak.

Frequently asked questions

›
›
›
›
›

References

Take Our Free 2-min Assessment
Start now